Health-economic evaluation of home telemonitoring for COPD in Germany: evidence from a large population-based cohort

Dmitrij Achelrod, Jonas Schreyögg, Tom Stargardt, Dmitrij Achelrod, Jonas Schreyögg, Tom Stargardt

Abstract

Introduction: Telemonitoring for COPD has gained much attention thanks to its potential of reducing morbidity and mortality, healthcare utilisation and costs. However, its benefit with regard to clinical and economic outcomes remains to be clearly demonstrated.

Objective: To analyse the effect of Europe's largest COPD telemonitoring pilot project on direct medical costs, health resource utilisation and mortality at 12 months.

Methods: We evaluated a population-based cohort using administrative data. Difference-in-difference estimators were calculated to account for time-invariant unobservable heterogeneity after removing dissimilarities in observable characteristics between the telemonitoring and control group with a reweighting algorithm.

Results: The analysis comprised 651 telemonitoring participants and 7047 individuals in the standard care group. The mortality hazards ratio was lower in the intervention arm (HR 0.51, 95 % CI 0.30-0.86). Telemonitoring cut total costs by 895 € (p < 0.05) compared to COPD standard care, mainly driven by savings in COPD-related hospitalisations in (very) severe COPD patients (-1056 €, p < 0.0001). Telemonitoring enrolees used healthcare (all-cause and COPD-related) less intensely with shorter hospital stays, fewer inpatient stays and smaller proportions of people with emergency department visits and hospitalisations (all p < 0.0001). Reductions in mortality, costs and healthcare utilisation were greater for (very) severe COPD cases.

Conclusion: This is the first German study to demonstrate that telemonitoring for COPD is a viable strategy to reduce mortality, healthcare costs and utilisation at 12 months. Contrary to widespread fear, reducing the intensity of care does not seem to impact unfavourably on health outcomes. The evidence offers strong support for introducing telemonitoring as a component of case management.

Keywords: Administrative data; COPD; Cost-effectiveness; Telemonitoring.

Conflict of interest statement

JS and TS have received funding for conducting the formal programme evaluation that this manuscript is based upon from AOK Bayern, a sickness fund, and SHL Telemedizin, a company offering telemonitoring services.

Figures

Fig. 1
Fig. 1
Flow-chart showing algorithm for selection of study population

References

    1. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 2012;379:1341–1351. doi: 10.1016/S0140-6736(11)60968-9.
    1. Menn P, Heinrich J, Huber RM, Jörres RA, John J, Karrasch S, Peters A, Schulz H, Holle R. KORA Study Group: direct medical costs of COPD—an excess cost approach based on two population-based studies. Respir. Med. 2012;106:540–548. doi: 10.1016/j.rmed.2011.10.013.
    1. Geldmacher H, Biller H, Herbst A, Urbanski K, Allison M, Buist AS, Hohlfeld JM, Welte T. The prevalence of chronic obstructive pulmonary disease (COPD) in Germany. Results of the BOLD study. Dtsch. Med. Wochenschr. 2008;133:2609–2614. doi: 10.1055/s-0028-1105858.
    1. Pritzkuleit R, Beske F, Katalinic A. Disease numbers in pneumology—a projection to 2060. Pneumologie. 2010;64:535–540. doi: 10.1055/s-0030-1255637.
    1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442. doi: 10.1371/journal.pmed.0030442.
    1. Achelrod D. Policy expectations and reality of telemedicine—a critical analysis of health care outcomes, costs and acceptance for congestive heart failure. J. Telemed. Telecare. 2014;20:192–200. doi: 10.1177/1357633X14533894.
    1. Bolton CE, Waters CS, Peirce S, Elwyn G. EPSRC and MRC Grand Challenge Team: insufficient evidence of benefit: a systematic review of home telemonitoring for COPD. J. Eval. Clin. Pract. 2011;17:1216–1222. doi: 10.1111/j.1365-2753.2010.01536.x.
    1. McLean S, Nurmatov U, Liu JLY, Pagliari C, Car J, Sheikh A. Telehealthcare for chronic obstructive pulmonary disease: Cochrane review and meta-analysis. Br. J. Gen. Pract. 2012;62:e739–e749. doi: 10.3399/bjgp12X658269.
    1. Cruz J, Brooks D, Marques A. Home telemonitoring effectiveness in COPD: a systematic review. Int. J. Clin. Pract. 2014;68:369–378. doi: 10.1111/ijcp.12345.
    1. Polisena J, Tran K, Cimon K, Hutton B, McGill S, Palmer K, Scott RE. Home telehealth for chronic obstructive pulmonary disease: a systematic review and meta-analysis. J. Telemed. Telecare. 2010;16:120–127. doi: 10.1258/jtt.2009.090812.
    1. Pedone C, Lelli D. Systematic review of telemonitoring in COPD: an update. Pneumonol. Alergol. Pol. 2015;83:476–484. doi: 10.5603/PiAP.2015.0077.
    1. Henderson C, Knapp M, Fernández J-L, Beecham J, Hirani SP, Cartwright M, Rixon L, Beynon M, Rogers A, Bower P, Doll H, Fitzpatrick R, Steventon A, Bardsley M, Hendy J, Newman SP. Whole system demonstrator evaluation team: cost effectiveness of telehealth for patients with long-term conditions (Whole Systems Demonstrator telehealth questionnaire study): nested economic evaluation in a pragmatic, cluster randomised controlled trial. BMJ. 2013;346:f1035. doi: 10.1136/bmj.f1035.
    1. Stoddart A, van der Pol M, Pinnock H, Hanley J, McCloughan L, Todd A, Krishan A, McKinstry B. Telemonitoring for chronic obstructive pulmonary disease: a cost and cost-utility analysis of a randomised controlled trial. J. Telemed. Telecare. 2015;21:108–118. doi: 10.1177/1357633X14566574.
    1. Hofer, F., Achelrod, D., Stargardt, T.: Cost-utility analysis of telemonitoring interventions for patients with chronic obstructive pulmonary disease (COPD) in Germany. Appl. Health Econ. Health Policy (2016). doi:10.1007/s40258-016-0267-9
    1. Federal Statistical Office . Population and employment—life table Germany 2009/11. Wiesbaden: Federal Statistical Office; 2013.
    1. Hainmueller J. Entropy balancing for causal effects: a multivariate reweighting method to produce balanced samples in observational studies. Polit. Anal. 2012;20:25–46. doi: 10.1093/pan/mpr025.
    1. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat. Med. 2009;28:3083–3107. doi: 10.1002/sim.3697.
    1. Bertrand M, Duflo E, Mullainathan S. How much should we trust differences-in-differences estimates? Q. J. Econ. 2004;119:249–275. doi: 10.1162/003355304772839588.
    1. Ringbaek T, Seersholm N, Viskum K. Standardised mortality rates in females and males with COPD and asthma. Eur. Respir. J. 2005;25:891–895. doi: 10.1183/09031936.05.00099204.
    1. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med. Care. 1998;36:8–27. doi: 10.1097/00005650-199801000-00004.
    1. Kuo RN, Dong Y-H, Liu J-P, Chang C-H, Shau W-Y, Lai M-S. Predicting healthcare utilization using a pharmacy-based metric with the WHO’s anatomic therapeutic chemical algorithm. Med. Care. 2011;49:1031–1039. doi: 10.1097/MLR.0b013e31822ebe11.
    1. Austin PC, Stanbrook MB, Anderson GM, Newman A, Gershon AS. Comparative ability of comorbidity classification methods for administrative data to predict outcomes in patients with chronic obstructive pulmonary disease. Ann. Epidemiol. 2012;22:881–887. doi: 10.1016/j.annepidem.2012.09.011.
    1. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C, Saunders LD, Beck CA, Feasby TE, Ghali WA. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med. Care. 2005;43:1130–1139. doi: 10.1097/01.mlr.0000182534.19832.83.
    1. Ten Have TR, Normand SLT, Marcus SM, Brown CH, Lavori P, Duan N. Intent-to-treat vs. non-intent-to-treat analyses under treatment non-adherence in mental health randomized trials. Psychiatr. Ann. 2008;38:772–783. doi: 10.3928/00485713-20081201-10.
    1. Steventon A, Bardsley M, Billings J, Dixon J, Doll H, Hirani S, Cartwright M, Rixon L, Knapp M, Henderson C, Rogers A, Fitzpatrick R, Hendy J, Newman S. Whole system demonstrator evaluation team: effect of telehealth on use of secondary care and mortality: findings from the Whole System Demonstrator cluster randomised trial. BMJ. 2012;344:e3874. doi: 10.1136/bmj.e3874.
    1. De Toledo P, Jiménez S, del Pozo F, Roca J, Alonso A, Hernandez C. Telemedicine experience for chronic care in COPD. IEEE Trans. Inf Technol. Biomed. 2006;10:567–573. doi: 10.1109/TITB.2005.863877.
    1. Bourbeau J, Julien M, Maltais F, Rouleau M, Beaupré A, Bégin R, Renzi P, Nault D, Borycki E, Schwartzman K, Singh R, Collet J-P. Chronic Obstructive Pulmonary Disease axis of the Respiratory Network Fonds de la Recherche en Santé du Québec: reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch. Intern. Med. 2003;163:585–591. doi: 10.1001/archinte.163.5.585.
    1. Trappenburg JCA, Niesink A, de Weert-van Oene GH, van der Zeijden H, van Snippenburg R, Peters A, Lammers J-WJ, Schrijvers AJP. Effects of telemonitoring in patients with chronic obstructive pulmonary disease. Telemed. J. E Health. 2008;14:138–146. doi: 10.1089/tmj.2007.0037.
    1. McKinstry B. The use of remote monitoring technologies in managing chronic obstructive pulmonary disease. QJM. 2013;106:883–885. doi: 10.1093/qjmed/hct068.
    1. Zwerink M, Brusse-Keizer M, van der Valk PDLPM, Zielhuis GA, Monninkhof M, van der Palen J, Frith PA, Effing T. Self management for patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2014;3:CD002990.
    1. Wilkinson TMA, Donaldson GC, Hurst JR, Seemungal TAR, Wedzicha JA. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004;169:1298–1303. doi: 10.1164/rccm.200310-1443OC.
    1. Paré G, Poba-Nzaou P, Sicotte C, Beaupré A, Lefrançois É, Nault D, Saint-Jules D. Comparing the costs of home telemonitoring and usual care of chronic obstructive pulmonary disease patients: a randomized controlled trial. Eur. Res. Telemed. 2013;2:35–47. doi: 10.1016/j.eurtel.2013.05.001.
    1. Haesum LKE, Soerensen N, Dinesen B, Nielsen C, Grann O, Hejlesen O, Toft E, Ehlers L. Cost-utility analysis of a telerehabilitation program: a case study of COPD patients. Telemed. J. E Health. 2012;18:688–692. doi: 10.1089/tmj.2011.0250.
    1. Pinnock H, Hanley J, McCloughan L, Todd A, Krishan A, Lewis S, Stoddart A, van der Pol M, MacNee W, Sheikh A, Pagliari C, McKinstry B. Effectiveness of telemonitoring integrated into existing clinical services on hospital admission for exacerbation of chronic obstructive pulmonary disease: researcher blind, multicentre, randomised controlled trial. BMJ. 2013;347:f6070. doi: 10.1136/bmj.f6070.
    1. McLean S, Chandler D, Nurmatov U, Liu J, Pagliari C, Car J, Sheikh A. Telehealthcare for asthma: a Cochrane review. CMAJ. 2011;183:E733–E742. doi: 10.1503/cmaj.101146.
    1. Anthonisen NR, Connett JE, Enright PL, Manfreda J. Lung Health Study Research Group: hospitalizations and mortality in the Lung Health study. Am. J. Respir. Crit. Care Med. 2002;166:333–339. doi: 10.1164/rccm.2110093.
    1. Achelrod D, Welte T, Schreyögg J, Stargardt T. Costs and outcomes of the German disease management programme (DMP) for chronic obstructive pulmonary disease (COPD)—a large population-based cohort study. Health Policy. 2016
    1. Rubin DB. Formal mode of statistical inference for causal effects. J. Stat. Plan. Inference. 1990;25:279–292. doi: 10.1016/0378-3758(90)90077-8.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren